Moreover, the SURMOUNT–MMO (tirzepatide, NCT05556512) will assess the impact of the dual GLP-1/GIP RA in cardiovascular outcomes and all-cause mortality for people with obesity (without diabetes) when the REDEFINE-3 study will assess the impact of cagrisema in people with obesity (with and without T2DM) and established cardiovascular disease. Here, GLP1R is linked to diabetes mellitus.